Stock Research for AMRN

AMRN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AMRN Stock Chart & Research Data

The AMRN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMRN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMRN Due diligence Resources & Stock Charts

The AMRN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMRN Detailed Price Forecast - CNN Money CNN View AMRN Detailed Summary - Google Finance
Yahoo View AMRN Detailed Summary - Yahoo! Finance Zacks View AMRN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AMRN Trends & Analysis - Trade-Ideas Barrons View AMRN Major Holders - Barrons
NASDAQ View AMRN Call Transcripts - NASDAQ Seeking View AMRN Breaking News & Analysis - Seeking Alpha
Spotlight View AMRN Annual Report - CompanySpotlight.com OTC Report View AMRN OTC Short Report - OTCShortReport.com
TradeKing View AMRN Fundamentals - TradeKing Charts View AMRN SEC Filings - Bar Chart
WSJ View Historical Prices for AMRN - The WSJ Morningstar View Performance/Total Return for AMRN - Morningstar
MarketWatch View the Analyst Estimates for AMRN - MarketWatch CNBC View the Earnings History for AMRN - CNBC
StockMarketWatch View the AMRN Earnings - StockMarketWatch MacroAxis View AMRN Buy or Sell Recommendations - MacroAxis
Bullish View the AMRN Bullish Patterns - American Bulls Short Pains View AMRN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AMRN Stock Mentions - StockTwits PennyStocks View AMRN Stock Mentions - PennyStockTweets
Twitter View AMRN Stock Mentions - Twitter Invest Hub View AMRN Investment Forum News - Investor Hub
Yahoo View AMRN Stock Mentions - Yahoo! Message Board Seeking Alpha View AMRN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AMRN - SECform4.com Insider Cow View Insider Transactions for AMRN - Insider Cow
CNBC View AMRN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMRN - OTC Markets
Yahoo View Insider Transactions for AMRN - Yahoo! Finance NASDAQ View Institutional Holdings for AMRN - NASDAQ


Stock Charts

FinViz View AMRN Stock Insight & Charts - FinViz.com StockCharts View AMRN Investment Charts - StockCharts.com
BarChart View AMRN Stock Overview & Charts - BarChart Trading View View AMRN User Generated Charts - Trading View




Latest Financial News for AMRN


The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Posted on Sunday September 16, 2018

Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...


REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association
Posted on Wednesday September 12, 2018

BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that the primary results of Amarin’s cardiovascular outcomes study of Vascepa, the REDUCE-IT study, have been accepted for presentation at the 2018 Scientific Sessions of American Heart Association (AHA) on November 10, 2018 in Chicago, Illinois.  The presentation, classified as late-breaking clinical trial results, is scheduled to commence at 2:16 pm Central Time and listed as Main Event 1 for that timeframe.  A link to this notice is provided at: http://www.abstractsonline.com/pp8/#!/4682/presentation/59402. This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention.  The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study.  As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018.


What Does Amarin Corporation plc’s (NASDAQ:AMRN) Ownership Structure Look Like?
Posted on Tuesday September 11, 2018

A look at the shareholders of Amarin Corporation plc (NASDAQ:AMRN) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...


Will Amarin Reward Patient Investors?
Posted on Saturday September 08, 2018

Results from a pivotal cardiovascular study are expected soon.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.